Full Breakdown
Shifting Trends in Cocaine Use and the Rise of Psychedelics in America
4/22/2026, 2:12:17 AM
Declining Cocaine Use Among Younger Generations
Cocaine, once a symbol of American excess since its rise in the 1970s, is witnessing a significant decline in usage, particularly among Generation Z. The National Survey on Drug Use reported that cocaine use dropped from 6.7% in the 1980s to just 1.5% in 2024, with 4.3 million adults admitting to use, down from 5.9 million in 2017. Notably, usage among 18- to 25-year-olds plummeted from 2.1 million in 2017 to 811,000 in 2024. Max Daly, a former global drugs editor at Vice, noted that younger individuals perceive cocaine as ethically questionable and associate it with heavy drinking and nightlife culture, which they are increasingly rejecting.
Cultural Shifts and Alternative Substances
The perception of cocaine as dangerous has intensified, particularly due to fears of contamination with fentanyl, a potent opioid. Andrew Yockey, an assistant professor at the University of Mississippi, highlighted that this unpredictability has made even occasional use seem risky. Concurrently, many young adults are gravitating towards alternatives like cannabis and prescription stimulants such as Adderall. The club scene is also evolving, with ketamine and various psychedelics gaining popularity as perceived safer options. A long-time raver noted that ketamine often leaves a more positive impact compared to cocaine, which can exacerbate anxiety and depression.
The Evolving Drug Landscape
The U.S. drug landscape is shifting towards a mixed-drug environment, with cocaine losing its prominence. Ed Sisco, a research chemist, indicated that the average purity of seized cocaine has increased significantly, leading to a rise in overdose deaths from 10,475 in 2016 to 22,174 in 2024, according to the Centers for Disease Control and Prevention. Despite the decline in cocaine use, the increase in overdose deaths has raised concerns, with some attributing it to the rise of "speedballs," a combination of cocaine and fentanyl.
Federal Actions on Psychedelics
In a related development, President Donald Trump signed an executive order aimed at accelerating research on psychedelics, including ibogaine, which has shown promise for treating conditions like PTSD and opioid addiction. This order directs the Department of Health and Human Services to allocate at least $50 million to states developing psychedelic programs. While the order has been met with cautious optimism, experts warn that ibogaine's known cardiotoxicity poses significant risks, complicating its study and potential approval.
Criticism and Concerns
Despite the potential benefits of psychedelics, critics express concern over the safety and efficacy of these substances. Frederick Barrett from Johns Hopkins University emphasized the need for rigorous scientific research to determine whether ibogaine is a superior therapeutic option. Additionally, the slow-moving federal processes surrounding drug classification and research could hinder the progress of both psychedelics and cannabis reform.
Conclusion: A New Era in Drug Use
As cocaine's cultural cachet wanes and overdose deaths rise, the U.S. appears to be moving towards a more complex drug landscape, where psychedelics may play a significant role in addressing mental health issues. The shift away from cocaine could signal a broader change in drug use patterns globally, as younger generations seek alternatives that align more closely with their values and health consciousness.
